Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
about
Radioisotopes for metastatic bone painApplications of 211At and 223Ra in targeted alpha-particle radiotherapyFrom palliative therapy to prolongation of survival: (223)RaCl2 in the treatment of bone metastasesTargeting Bone Metastases in Metastatic Castration-Resistant Prostate CancerHybrid Imaging for Patient-Specific Dosimetry in Radionuclide TherapyCombining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapyEvolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223Targeting bone physiology for the treatment of metastatic prostate cancerEvolving landscape and novel treatments in metastatic castrate-resistant prostate cancerRecent progress in pharmaceutical therapies for castration-resistant prostate cancerRadium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case PresentationRadionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerNovel non-AR therapeutic targets in castrate resistant prostate cancerThe elements of life and medicinesRadium-223 dichloride in clinical practice: a review.Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial.Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.WITHDRAWN: Radioisotopes for metastatic bone pain.Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant diseaseA high-throughput screen for alpha particle radiation protectants.Recent advances in bone-targeted therapies of metastatic prostate cancerPhase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.Bone-targeting agents in prostate cancer.Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters.Emerging treatment options for patients with castration-resistant prostate cancer.Evolving role of bone biomarkers in castration-resistant prostate cancer.Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases.Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma.Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.Systemic targeted alpha radiotherapy for cancer.CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Targeted alpha anticancer therapies: update and future prospectsAlpha particles induce apoptosis through the sphingomyelin pathway.Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab.
P2860
Q24235589-DE4CEB96-5B8A-45AF-A4A3-C3D7ABBA7CCEQ24610016-5B5005A6-A477-44B9-8BE4-B9F229121D1AQ26740064-2E982F93-764E-433E-B3C0-B9B160674034Q26752785-36B7F34B-720B-4947-BEE0-AF547C64779AQ26768478-110F3FC2-BE10-4BFB-9F81-5B324C31971DQ26851608-9879E740-62FE-460E-B95F-3F3CEB462A96Q26861575-F7FED1DB-9FE2-4ED8-97B6-53136549ECB8Q26863249-1D652174-E075-4BEB-AA75-B7A4B6FFF39AQ27010542-30ED9D91-A2F7-4E05-BD12-4BAA82848151Q27022567-2F45AEA7-4B2A-4398-8E30-3CB9E2F94BADQ28077633-7C8E2845-DD7E-4F5F-A681-3AA7A1F4A94CQ28079918-9AB7E9ED-FE7F-4170-9B6A-1AFE4BBB5F4DQ28383663-33F1EE83-D17B-4823-8F93-B31FD9EDF848Q28649323-456B5198-81B2-4034-8124-1CAFAE12A2F5Q30251496-0FCAAD81-4CD1-4AE9-B001-6E5645B55E71Q30521133-314E37CC-D7F5-4AF5-88D5-DE67A93F25DFQ33405335-8622A7B9-C7BB-4B38-9918-9AE35026AB41Q33408024-276BC562-2CE8-4DCC-9AC4-1492F9FAD1D6Q33419685-2BE89396-FE14-4415-80EC-82AE9CCA83A3Q33437726-1365ADE2-0C9F-4967-AA27-D7AD8D3C921BQ33440341-C952F71A-FF41-4971-B7BC-7E6EDFE951AEQ33441176-2FDE00F4-7B39-42F0-9BB3-345B2CFA89FEQ33628466-AB6AEF25-6C54-433C-96F5-C067FFB0A851Q33640606-CF4E4108-A93A-4568-B301-71820990E51CQ33703763-F082D2E4-51E9-4840-A696-92B94AE8911FQ33789188-91C2CC0F-D59B-45E2-BCF0-E5A2A5129CA7Q33864723-2855CE7B-3CEE-44D0-8BCC-DFC9DFF1E1D0Q33942600-2DBE082A-8FF3-428C-803D-F1D045CDCE82Q33958519-B8A38AC0-042E-4955-97AF-68F2193E9D29Q34023877-A5E4A9DB-5EB2-46D9-BE3C-9DD71F003B30Q34243421-26C00978-848A-434B-B88D-384FBF2F5C26Q34323756-355A013D-AFD8-4568-9FC0-8846348F7F82Q34348226-5CF7F55D-C881-4352-B724-52D4FA60C854Q34374096-5A5EC268-851A-4700-8B87-545C3294CD15Q34377594-5F33F5B8-7749-42F8-ADD1-CB7E778A24E4Q34387852-2F67EBB4-34FC-46E3-BDBA-1AF2A64B3A7FQ34511439-E80E709B-21CB-4492-ADEA-2A735BFC8555Q35258065-7DD7067B-CB06-4A54-BE4C-143913E6B90DQ35623683-97B46BEC-7260-4057-BAB1-FAC2F3180169Q35650472-22E209A4-D898-42D2-B3A2-249E31FFF8DD
P2860
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.
@ast
Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.
@en
Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.
@nl
type
label
Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.
@ast
Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.
@en
Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.
@nl
prefLabel
Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.
@ast
Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.
@en
Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.
@nl
P2093
P1433
P1476
Bone-targeted radium-223 in sy ...... ebo-controlled phase II study.
@en
P2093
Bjørg Bolstad
Bo Lennernäs
Christopher Parker
Christopher Tyrrell
Dag C Johannessen
Jan Tennvall
Jeffrey Yachnin
Johan Harmenberg
Katharine Pigott
Lars Franzén
P304
P356
10.1016/S1470-2045(07)70147-X
P577
2007-07-01T00:00:00Z